Clinical trials: HCC
Advanced Hepatocellular Carcinoma
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da.
- Trial name
- NCT04066660
- Testing
- Oligo Fucoidan
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Hi-Q Marine Biotech International, Ltd.
Hepatocellular Carcinoma
The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead
This study involves the combined use of the FDA approved device, LC Bead and the FDA approved drug, Doxorubicin for the treatment of primary hepatocellular carcinoma (HCC).
- Trial name
- NCT01259024
- Testing
- transarterial chemoembolization using a drug-eluting bead
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Adenocarcinoma of Prostate, Radical Prostatectomy
Multimodal Machine Learning Characterization of Solid Tumors
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.
- Conditions
- Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma
- Trial name
- NCT04687969
- Testing
- [18F]DCFPyL, PET/MRI scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ciprian Catana, MD, PhD
Hepatocellular Carcinoma
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
- Trial name
- NCT06961617
- Testing
- LioCyx-M, HBV antigen-specific TCR-redirected T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
HCC - Hepatocellular Carcinoma, Cirrhosis
Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma
This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study.
- Trial name
- NCT07036874
- Testing
- transient elastography and oesophagogastroduodenoscopy
- Where
- Hong Kong
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Cirrhosis
Comparison of Covered and Bare Stent in TIPS
Investigators aim to compare the efficacy of 8 mm Fluency covered stent and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of cirrhotic portal hypertension.
- Trial name
- NCT02540382
- Testing
- covered stent, bare stent
- Where
- China
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Beijing Shijitan Hospital, Capital Medical University
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatic Tumor
Multicenter Study to Evaluate a New Robotic Device for Image-guided Percutaneous Needle Placement
This study evaluates the safety and performance of a new robotic device in the treatment of hepatic thermoablation in adults. The new robotic device will be used in all patients.
- Trial name
- NCT04230642
- Testing
- The Quantum Surgical device
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Quantum Surgical
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00047346
- Testing
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant treatment for resectable advanced…
- Trial name
- SOURCE (NCT04143191)
- Testing
- Sorafenib, Transarterial chemoembolization
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular, Cirrhosis
Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
This clinical trial is aimed at extending the chance of liver transplantation, through downstaging procedures, to patients with hepatocellular carcinoma (HCC) exceeding conventional Milan Criteria.
- Trial name
- NCT01387503
- Testing
- Liver transplantation
- Where
- 10 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
HCC
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients with Hepatocellular Carcinoma at Risk of Recurrence after Surgical Resection.
- Trial name
- NCT06560827
- Testing
- CT011 CAR-GPC3 T Cells Injection
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Alcoholic Cirrhosis
National Cohort of Uncomplicated Alcoholic Cirrhosis
Hepatocellular carcinoma (HCC) is a major public health problem, whose incidence is increasing in developed countries and is the leading cause of death in patients with cirrhosis.
- Trial name
- CIRRAL (NCT01213927)
- Where
- France
- Volunteers
- 709 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
This is a prospective, non-interventional, observational study evaluating the efficacy and immune microenvironment changes in Patients with Advanced Hepatocellular Carcinoma treated with TACE Combined with PD-1 Inhibitor.
- Trial name
- TASK-01-RW (NCT07100405)
- Testing
- PD-1 inhibitor, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Vast majority of patients with hepatocellular carcinoma (HCC) present with unresectable disease. In the last decade results of randomized trials and a subsequent metaanalyses established transarterial chemoembolization (TACE) or…
- Trial name
- TACE-SBRT (NCT02794337)
- Testing
- SBRT, TACE, Sorafenib
- Where
- 2 sites in India
- Volunteers
- 67 people
- Sponsor
- Tata Memorial Hospital
Hepatocellular Carcinoma, Cirrhosis
Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
The new version of CEUS LI-RADS published at 2018(version 2017). In this study, the investigators aim to investigate the diagnosing performance of CEUS LI-RADS by administrating different contrast agents (SonoVue/ Sonazoid).
- Trial name
- NCT04006275
- Testing
- Sonovue and Sonazoid, Sonazoid and Sonovue
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis and screening.Relying on the…
- Trial name
- NCT06134973
- Testing
- ultrasonic testing
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Third Central Hospital
Primary Liver Carcinoma
Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Open label, single arm, multi-centre study of pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed.
- Trial name
- PETAL (NCT03397654)
- Testing
- Pembrolizumab, Trans-arterial chemoembolization
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Imperial College London
Hepatocellular Carcinoma
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation.
- Trial name
- NCT01918683
- Testing
- TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine